Pancreatic cancer is an extremely aggressive neoplasm whose incidence equals its death rate. Despite extensive analysis, no effective therapeutic approaches for diminishing the morbidity associated with this disease are available. By appropriate pharmacological manipulation, human melanoma cells can be induced to lose tumorigenic potential, irreversibly growth arrest and terminally differentiate. Through the use of subtraction hybridization, a novel gene associated with these changes in human melanoma cells, melanoma differentiation associated gene-7 (mda-7), has been identified. Ectopic expression of mda-7 using a recombinant adenovirus, Ad.mda-7, promotes growth suppression and apoptosis in diverse cancer cell types, including tumor cells with wild-type p53 or mutant for p53, Rb or p53 + Rb. Moreover, growth and progression of human breast, lung and cervical cancer cells in vivo in nude mice are inhibited by Ad.mda-7. In contrast, no deleterious effect is apparent following Ad.mda-7 infection of normal human cells. Selective induction of apoptosis in multiple tumor cell types correlates with an elevation in the level of the pro-apoptotic protein BAX and an increase in the ratio of BAX to BCL-2. In contrast to its apoptosis-inducing effects in the majority of human cancers, pancreatic carcinomas are refractory to Ad.mda-7. However, when Ad.mda-7 is combined with approaches that specifically inhibit expression of the K-ras oncogene, which is mutated in approximately 85 to approximately 95 percent of pancreatic carcinomas, a loss of viability by induction of apoptosis results. These intriguing observations suggest that a combinatorial approach consisting of a cancer-specific apoptosis-inducing gene and an oncogene inactivation strategy may provide the basis for developing an effective molecular-target based therapy for pancreatic cancer. Experiments will expand on these observations and determine the mechanism underlying the synergy and develop potential cancer therapeutic viruses, including Ads expressing a combination of mda-7 and antisense K-ras and an Ad displaying cancer-restricted replication and cytolytic activity in the context of pancreatic carcinoma cells. The present studies will provide the obligatory preclinical support for novel approaches with significant potential for rapid translation into rational methods for treating patients' afflicted with an invariably incurable disease, pancreatic cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA098712-01
Application #
6561863
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Perry, Mary Ellen
Project Start
2003-01-21
Project End
2007-12-31
Budget Start
2003-01-21
Budget End
2003-12-31
Support Year
1
Fiscal Year
2003
Total Cost
$363,788
Indirect Cost
Name
Columbia University (N.Y.)
Department
Pathology
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Dent, Paul; Yacoub, Adly; Hamed, Hossein A et al. (2010) MDA-7/IL-24 as a cancer therapeutic: from bench to bedside. Anticancer Drugs 21:725-31
Dent, Paul; Yacoub, Adly; Hamed, Hossein A et al. (2010) The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther 128:375-84
Yacoub, Adly; Hamed, Hossein A; Allegood, Jeremy et al. (2010) PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Res 70:1120-9
Walker, Teneille; Mitchell, Clint; Park, Margaret A et al. (2010) 17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species. Mol Cancer Ther 9:1378-95
Emdad, Luni; Lebedeva, Irina V; Su, Zhao-zhong et al. (2009) Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol Ther 8:391-400
Lebedeva, Irina V; Su, Zhao-zhong; Vozhilla, Nichollaq et al. (2008) Mechanism of in vitro pancreatic cancer cell growth inhibition by melanoma differentiation-associated gene-7/interleukin-24 and perillyl alcohol. Cancer Res 68:7439-47
Lebedeva, Irina V; Su, Zhao-Zhong; Vozhilla, Nichollaq et al. (2008) Chemoprevention by perillyl alcohol coupled with viral gene therapy reduces pancreatic cancer pathogenesis. Mol Cancer Ther 7:2042-50
Chan, Isaac; Lebedeva, Irina V; Su, Zao-Zhong et al. (2008) Progression elevated gene-3 promoter (PEG-Prom) confers cancer cell selectivity to human polynucleotide phosphorylase (hPNPase(old-35))-mediated growth suppression. J Cell Physiol 215:401-9
Lebedeva, Irina V; Washington, Ilyas; Sarkar, Devanand et al. (2007) Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas. Proc Natl Acad Sci U S A 104:3484-9
Sarkar, Devanand; Lebedeva, Irina V; Gupta, Pankaj et al. (2007) Melanoma differentiation associated gene-7 (mda-7)/IL-24: a 'magic bullet'for cancer therapy? Expert Opin Biol Ther 7:577-86

Showing the most recent 10 out of 42 publications